Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-TNF Monoclonal Antibody

Infliximab

Brand names: Remicade, Inflectra (biosimilar)

Used in: Inflammatory Bowel Disease

Infliximab is a chimeric monoclonal antibody and tumour necrosis factor (TNF) alpha inhibitor given by intravenous infusion to treat moderately to severely active Crohn's disease and ulcerative colitis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds to and neutralises soluble and membrane-bound TNF-alpha, a key pro-inflammatory cytokine, thereby reducing the chronic mucosal inflammation driving inflammatory bowel disease.

Prescribing in practice

  • Screen for and treat latent tuberculosis and viral hepatitis B before starting, as TNF inhibitors can reactivate serious infections; serious and opportunistic infections are the principal risk.
  • Infusion reactions and delayed hypersensitivity can occur, so infusions are given under supervision with facilities to manage reactions.
  • It is contraindicated in moderate to severe heart failure and in active serious infection, and live vaccines should be avoided during treatment.

Monitoring

Monitor for signs of infection, infusion reactions and heart failure throughout treatment, with tuberculosis screening before initiation.

Counselling the patient

  • Report fever, cough, weight loss or other signs of infection promptly, as this medicine lowers the body's ability to fight infection.
  • Tell any clinician you are receiving this medicine before having vaccinations, and avoid live vaccines.

Evidence & guidelines

Infliximab is recommended by NICE for treating moderately to severely active Crohn's disease and ulcerative colitis.

Reference: NICE TA187; ECCO IBD Guidelines 2021; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways